Aberrant expression of cancer genes and non-canonical RNA species is a hallmark of cancer. However, the mechanisms driving such atypical gene expression programs are incompletely understood. Here, our transcriptional profiling of a cohort of 50 primary clear cell renal cell carcinoma (ccRCC) samples from The Cancer Genome Atlas (TCGA) reveals that transcription read-through beyond the termination site is a source of transcriptome diversity in cancer cells. Amongst the genes most frequently mutated in ccRCC, we identified SETD2 inactivation as a potent enhancer of transcription read-through. We further show that invasion of neighbouring genes and generation of RNA chimeras are functional outcomes of transcription read-through. We identified the BCL2 oncogene as one of such invaded genes and detected a novel chimera, the CTSC-RAB38, in 20% of ccRCC samples. Collectively, our data highlight a novel link between transcription read-through and aberrant expression of oncogenes and chimeric transcripts that is prevalent in cancer.https://doi.org/10.7554/eLife.09214.001
Mutations in genes play important roles in many types of cancer. However, mutations alone cannot explain all the biological changes that occur to cancer cells. For example, very few mutations have been linked with a type of kidney cancer called clear cell renal cell carcinoma (or ccRCC for short). Instead, scientists suspect that this cancer is largely caused by changes in the expression of particular genes so that certain cancer-promoting genes are more highly expressed, while other genes that would prevent tumor growth become less active.
One of the few genes that is often mutated in ccRCC is called SETD2. This gene is involved in processes that alter the structure of DNA, but do not alter the genes themselves. These “epigenetic” changes can alter how the instructions in genes are used to make proteins. The first step in making proteins is to use a section of DNA as a template to make molecules of messenger ribonucleic acid (mRNA) in a process called transcription. There are markers within a gene that show where transcription should start and stop to produce the mRNA required to make a particular protein. Epigenetic changes can mask these markers so that the cell produces longer mRNAs that incorporate instructions from neighboring genes.
It was not known how often these stop signs are ignored in ccRCC cells. Here, Grosso et al. compared transcription in normal cells and in ccRCC tumor cells from 50 different patients. The experiments show that more stop signs were ignored in many of the cancer cells, especially in cells with mutations in SETD2. This caused all or parts of neighboring genes to be transcribed along with the target gene and led to changes in the expression levels of these genes. For example, a cancer-promoting gene called BCL2 was more highly expressed in these cells.
Furthermore, some of the mRNA molecules produced in these cancer cells may make “fusion” proteins that combine elements from several proteins. These fusion proteins may work differently to normal cell proteins and therefore might also promote the development of tumors. Grosso et al.’s findings reveal a new link between epigenetic changes and cancer.https://doi.org/10.7554/eLife.09214.002
Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal carcinoma. The genetics of ccRCC is dominated by either somatic or germline inactivating mutations in the VHL gene. Regarding the full spectrum of genomic alterations, ccRCC ranks amongst solid tumors with the lowest average number of point mutations, small indels (Kandoth et al., 2013) and somatic copy number alterations (Zack et al., 2013). These findings suggest that epigenetic events make a significant contribution for the deregulation of the oncogenic and tumor suppressor gene expression programs that drive ccRCC development and progression. In fact, mutations in ccRCC are frequently observed in epigenetic factors such as the chromatin-remodeler PBRM1 and the histone modifying enzymes BAP1 and SETD2, highlighting the central role of epigenetic regulation in this particular cancer (Duns et al., 2010; Varela et al., 2011; Dalgliesh et al., 2010; Creighton et al., 2013). Such mutations in genes that control the epigenome can strongly modulate the landscape of the tumor transcriptome via aberrant expression of global sets of genes. For instance, defects in transcription termination lead to read-through beyond the annotated 3’ gene boundary and have the potential to severely modify the transcriptome and to risk the integrity of vital gene expression programs (Kuehner et al., 2011). Paradoxically, the prevalence and functional outcome of transcription read-through has not been thoroughly scrutinized in any cancer before. Here, we report an unprecedented transcriptional profiling of a cohort of 50 pairs of ccRCC tumor and normal matched samples from The Cancer Genome Atlas (TCGA). We show that transcription read-through is prevalent in ccRCC and found that high levels of transcription read-through correlate with poor survival rates. Amongst the most frequently mutated genes in ccRCC, we identify SETD2 inactivation as a major driving force of impaired transcription termination and high levels of read-through. Moreover, we show that transcription read-through overruns and interferes with the expression of downstream genes. We identify the anti-apoptotic oncogene BCL2 as one of such interfered genes, thereby illustrating a new mechanistic basis for the transcriptional deregulation of oncogenes. In addition, our transcriptome analyses revealed recurrent RNA chimeras generated from read-through episodes in ccRCC. RNA chimeras are common features of cancer cells formerly thought to be produced solely by chromosomal translocations. We now know that many chimeric transcripts can originate from DNA-independent events such as trans-splicing, RNA recombination or transcription read-through (Gingeras, 2009). Our analyses revealed that read-through is a major source of RNA chimeras in ccRCC and identified a novel chimera, the CTSC-RAB38, in 20% of ccRCC tumors, but not in any normal matched sample. Altogether, our data disclose the prognostic power of transcription read-through and emphasizes its role as a major source of transcriptome diversity in ccRCC, namely via aberrant expression of cancer genes and RNA chimeras.
To investigate the prevalence of transcription read-through in ccRCC, we analysed RNA-seq data from 50 pairs of tumor and normal matched samples from TCGA (Cancer Genome Atlas Research N, 2013). Compared to normal tissue, all tumor samples exhibited several genes with transcription termination defects revealed by a high number of reads mapping downstream the transcription termination site (TTS) (Figure 1A,B and Supplementary file 1A). Such accumulation of reads results from transcription read-through beyond the TTS, a surrogate for deficient transcription termination (Higgs et al., 1983). In agreement with a defect in transcription termination, we did not detect differences in read counts on any region upstream the TTS, contrasting with the significant increase in the intergenic region immediately downstream this site (Figure 1C).
We then examined whether global deregulation of gene expression at the level of transcription termination affects overall survival rates of ccRCC patients. For that we segregated the TCGA samples into two categories: ‘high read-through’ samples (those with more than 200 genes with read-through) and ‘low read-through’ samples (less than 200 genes with read-through) (Figure 2A). We found that patients with a ‘high read-through’ phenotype died significantly earlier than patients with a ‘low read-through’ phenotype (p = 0.008, log-rank test; Figure 2B).
To estimate the contribution of the five most frequently mutated genes in ccRCC (Cancer Genome Atlas Research N, 2013) to the observed transcription termination defects, we calculated the percentage of samples carrying any of these mutations that fall within each of the two subsets defined above. Samples with mutations in the histone methyltransferase SETD2 scored preferentially in the ‘high read-through’ category (58%) (Figure 2C). In contrast, samples carrying any of the four other frequently mutated genes in ccRCC segregated equally between both groups (BAP1) or mainly in the ‘low read-through’ category (VHL, PBRM1, MTOR. Figure 2C). Mutations on other genes known to be required for transcription termination or pre-mRNA processing were rare and did not segregate specifically in any category (Supplementary file 1B). These data suggest that widespread transcription read-through is a distinctive hallmark of ccRCC and identify SETD2 mutations as a putative contributing factor for this phenotype.
To further investigate the correlation between SETD2 mutations and transcription read-through in ccRCC, we performed RNA sequencing of 2 SETD2 wild type (wt) and 4 SETD2 mutant ccRCC cell lines previously reported to have a marked reduction of H3K36me3 levels (Duns et al., 2010; Carvalho et al., 2014). The wt ccRCC cell line Caki2 showed the highest SETD2 expression levels, comparable with those of a non-cancer kidney epithelial cell line (HEK293) (Figure 3A). For this reason, we chose Caki2 as the reference dataset for the pairwise analyses of the remaining wt (Caki1) and mutant (MF, AB, ER, FG2) samples. These analyses revealed transcription read-through in hundreds of genes on all ccRCC cell lines, with a significantly higher incidence in all SETD2 mutant cells (Figure 3B and Supplementary file 1C). A metagene analysis of genes with transcription termination defects in SETD2 mutant cells revealed that expression levels vary significantly downstream the TTS, but not within the gene body or at the promoter region (Figure 3C). Moreover, heatmaps of the fold change of read counts between different cell lines depict a strong increase in the number of read-through reads in SETD2 mutant cells (Figure 3D and Figure 3—figure supplement 1). To rule out the contribution of different genetic backgrounds in these cell lines, we interrogated RNA-seq data from: SETD2 knockout (KO) ccRCC cells (Ho et al., 2015); SETD2-depleted human mesenchymal stem (MS) cells (Luco et al., 2010); and embryonic stem (ES) cells from Setd2 KO mice (Zhang et al., 2014). Again, when compared to wt cells, SETD2-deficient cells displayed increased read counts specifically in the region immediately downstream the TTS consistent with transcription read-through events (Figure 3E,F; Figure 3—figure supplement 2 and Supplementary file 1D,E,F). Similar results were obtained upon RT-qPCR measurements of transcription read-through in three distinct genes 48 hr after depletion of SETD2 from wt ccRCC cells by RNA interference (Figure 3—figure supplement 3)
We then investigated whether wt SETD2 can rescue the transcription termination defects observed in SETD2 mutant ccRCC cells. For that, we performed single-molecule RNA FISH after transient expression of GFP-tagged SETD2 in a SETD2 mutant ccRCC cell line (Figure 4A). RNAs produced upon transcription read-through of MRPL23 and SEL1L3 were visualized as foci obtained with RNA FISH probes targeting a region downstream the termination site. These foci were present in significantly higher number in GFP-negative cells than in wt SETD2-GFP expressing cells (Figure 4B). This result reveals that expression of wt SETD2 is sufficient to revert the transcription termination defects observed in mutant cells. Altogether, these data support the view that SETD2 is necessary to guide correct transcription termination genome-wide and that mutations in this histone modifier gene cause aberrant transcription patterns in ccRCC.
One possible functional consequence of aberrant transcription read-through is the invasion of adjacent downstream genes altering their expression levels. This trans-acting transcriptional interference mechanism may play important roles in cancer development and progression by deregulating the expression of relevant oncogenes and tumor suppressors (Proudfoot, 1986). To test whether overrunning of neighbouring genes is a frequent outcome of transcription read-through in ccRCC, we analysed the expression levels of the entire intergenic region and of the gene located immediately downstream. In agreement with our prediction, there was a statistically significant increase in read counts along the intergenic region and within the body of the downstream gene of a tandem pair (Figure 5A). This difference was still detected after the TTS of the downstream gene, but not within the upstream gene (Figure 5B). Overall, reading-through RNA polymerase II (RNAPII) molecules invaded an average of 20% of genes located downstream (Supplementary file 1A).
We then asked if read-through levels correlate with the expression levels of the downstream gene across the TCGA dataset. Notably, expression of 52 out of 903 genes (6%) exhibited a statistically significant correlation with read-through levels of the upstream gene (Figure 6A, Supplementary file 1G). From these, 51 genes were positively correlated and only one gene showed a negative correlation. Amongst positively correlated genes we found the anti-apoptotic oncogene BCL2. In support of its oncogenic role in kidney cancer, depletion of BCL2 with antisense oligonucleotides inhibits ccRCC tumor growth in vitro and in vivo (Uchida et al., 2001). We further observed that expression of BCL2 is frequently increased in the tumor samples of the TCGA dataset when compared to the matched samples (Figure 6B). Importantly, augmented levels of BCL2 mRNA and protein correlated positively with the levels of transcription read-through of the KDSR gene located immediately upstream (Figure 6B,C). Altogether, these data suggest that transcription termination defects interfere with the expression of neighbouring genes and illustrate a new paradigm for the aberrant expression of cancer-related genes, which may explain the upregulation of the BCL2 oncogene in ccRCC.
RNAPII elongation beyond the annotated gene boundaries and invasion of an adjacent gene as a result of impaired transcription termination may result in the formation of hybrid transcripts collectively called RNA chimeras (Gingeras, 2009). In addition to gene fusions (formed upon chromosomal translocations) RNA chimeras can originate from DNA-independent events such as trans-splicing, RNA recombination or transcriptional read-through (Gingeras, 2009). Our analysis of ccRCC RNA-seq data revealed a high number of reads mapping at two distinct tandem genes, which are indicative of RNA chimeras generated by intergenic splicing following a read-through event (Figure 7A, Supplementary file 1H). Analysis of the splicing pattern of these chimeras showed that most events join the second-last exon of the upstream gene with the second exon of the downstream gene (Figure 7B). This pattern is compatible with the exon definition model according to which transcription termination is necessary for the selection of the terminal 3’ splice site (ss) (Niwa et al., 1992; Dye and Proudfoot, 1999). In the absence of transcription termination, the terminal 3’ss is evicted and the terminal 5’ss will splice together with the first 3’ss of the downstream gene, which emerges from the nascent transcript once RNAPII reaches the second exon (Figure 7B). Interestingly, the number of RNA chimeras detected correlated positively with the levels of transcription read-through (p = 0.003; R = 0.41) and was significantly higher in the sample group with a ‘high read-through’ phenotype defined above (Figure 7C).
A remarkable feature of these RNA chimeras is that some were recurrently detected in different tumor samples. One particular chimera, encoded by two consecutive genes - CTSC and RAB38 - was detected in 20% of the TCGA samples (but not in any matched normal sample) and in four of the six ccRCC cell lines that we sequenced de novo (Supplementary file 1H). We validated this RNA chimera by RT-qPCR before and after transfection of the ccRCC cell lines with a small interfering RNA (siRNA) spanning the transcript break-point, which resulted in a robust depletion of CTSC-RAB38 (Figure 8A,B). In contrast, siRNAs targeting either the last exon of CTSC or the first exon of RAB38 (which are not included in the chimeric transcript) significantly decreased the levels of CTSC and RAB38, respectively, but not the levels of the CTSC-RAB38 chimera (Figure 8B,C). Moreover, we measured the RNAPII occupancy throughout the intergenic region and within the body of the CTSC and RAB38 genes by chromatin immunoprecipitation (ChIP). We detected a robust occupancy of RNAPII throughout the intergenic region (Figure 8D), which further suggests that the CTSC-RAB38 chimera is generated following a read-through episode without any genomic deletion or translocation involved.
Our transcriptome analysis of a large dataset of tumor and normal matched samples revealed that transcription events extending beyond the annotated 3’ end of genes are frequent in ccRCC. Strikingly, our analysis further disclosed an unexpected prognostic power of transcription read-through in kidney cancer: higher number of genes with transcription read-through correlates significantly with poorer patient survival. Amongst the most frequently mutated genes in ccRCC, we identified SETD2 inactivation as a contributing factor for increased transcription read-through. In fact, ectopic expression of SETD2 was sufficient to rescue the transcription termination defects of SETD2 mutant ccRCC cells. Moreover, we report that the effects of impaired transcription termination are not confined to the affected gene. Instead, it also contaminates the expression of neighboring genes that are overran by reading-through RNAPII complexes. Importantly, amongst the genes whose expression directly correlates with the volume of transcription read-through on the upstream gene, we detected the anti-apoptotic oncogene BCL2. This finding unveils a new source of aberrant expression of cancer-related genes and provides a plausible mechanistic basis for the upregulation of BCL2 frequently observed in ccRCC.
Our present study further reveals recurrent RNA chimeras in ccRCC combining sequences from two tandem genes. Such chimeras are generated following extensions of RNAPII beyond the annotated gene boundaries and invasion of an adjacent gene as a result of impaired transcription termination. According to the exon definition model (Niwa et al., 1992; Dye and Proudfoot, 1999), deficient transcription termination is expected to impair the splicing of the last exon. In agreement, most chimeras skip the last exon of the upstream gene and the prevailing splicing pattern joins the second-last exon of the upstream gene with the second exon of the downstream gene. The finding that several of these RNA chimeras are recurrently detected in two or more tumor samples, suggests that they were selected during cancer development and supports the exciting possibility that they may play relevant functional roles.
Although our study primarily focused on the characterization of the transcription termination defects and their impact on the ccRCC transcriptome, our pioneer findings raise intriguing questions such as: which mechanism(s) drive such transcription defects?; how individual RNA chimeras are functionally involved in tumorigenesis?; do chimeric transcripts produce functional oncoproteins and/or can they directly affect the expression of other relevant cancer genes?; how can we intervene therapeutically to restore the canonical transcription pattern? The widespread incidence of aberrant termination in ccRCC cells suggests that it may play important roles in expanding the transcriptome diversity that drives cancer development and progression. The impact on BCL2 expression illustrates a relevant functional outcome of transcription read-though. The generation of chimeric transcripts, namely those recurrently identified in several samples, such as CTSC-RAB38, further discloses the contribution of impaired transcription termination for the expansion of RNA species that may favor cancer progression. Nevertheless, future studies should provide direct evidence that a chimeric transcript has oncogenic functions in order to support the physiological relevance of these RNAs. This is a challenging and very exciting topic and further efforts are required to fully elucidate the impact of impaired transcription termination on cancer in general and on ccRCC in particular.
ccRCC cells (Caki-1, Caki-2, MF, ER, AB and FG2, Cell Line Services Eppelheim, Germany) were grown as monolayers in Dulbecco’s modified Eagle medium (DMEM, Invitrogen, CA, USA), supplemented with 10% (v/v) FBS, 1% (v/v) nonessential amino acids, 1% (v/v) L-glutamine and 100U/ml penicillin-streptomycin, and maintained at 37°C in a humidified atmosphere with 5% CO2.
RNAi was achieved using synthetic siRNA duplexes (Eurogentec, Belgium). The sequence of the siRNAs is shown in Supplementary file 1I. siRNAs targeting the firefly luciferase (GL2) were used as controls. Cells were reverse transfected with 10 μM siRNAs using OptiMEM (Invitrogen) and Lipofectamine RNAiMAX (Invitrogen), according to the manufacturer’s instructions. 24 hr after the first transfection, cells were re-transfected with the same siRNA duplexes and transfection reagents and harvested on the following day.
Total RNA was extracted with TRIzol (Invitrogen). cDNA was made using Superscript II Reverse Transcriptase (Invitrogen). RT-qPCR was performed in the ViiA Real Time PCR (Applied Biosystems, CA, USA), using SYBR Green PCR master mix (Applied Biosystems). The relative RNA expression was estimated as follows: 2^(Ct reference – Ct sample), where Ct reference and Ct sample are mean threshold cycles of RT-qPCR done in duplicate on cDNA samples from U6 snRNA (reference) and the cDNA from the genes of interest (sample). All primer sequences are presented in Supplementary file 1I.
ChIP was performed as described (de Almeida et al., 2011). The relative occupancy of RNAPII at each locus was estimated by RT-qPCR as follows: 2^(Ct Input – Ct IP), where Ct Input and Ct IP are mean threshold cycles of RT-qPCR done in duplicate on DNA samples from input and specific immunoprecipitations, respectively. RNAPII was precipitated with an antibody against its largest subunit (N20, sc-899; Santa Cruz, TX, USA). The sequences of gene-specific, intergenic regions and gene desert primer pairs are presented in Supplementary file 1I.
FG2 ccRCC cells were transiently transfected with a wt SETD2-GFP expression plasmid (Carvalho et al., 2014) and cultured on glass coverslip for 24 hr before hybridization with RNA FISH probes (Biosearch Technologies, CA, USA) following the manufacturer’s protocol. Briefly, cells were washed with PBS, fixed for 10 min at room temperature, washed twice with PBS, and permeabilized at 4°C in 70% (vol/vol) EtOH. Probes diluted in hybridization buffer were added to permeabilized cells before overnight incubation in a dark chamber at 37°C. After washing, DAPI was added to stain the nuclei. Epi-fluorescence microscopy was performed using a Zeiss Z1 microscope equipped with Z-piezo (Prior, MA, USA), a 63x 1.4 NA Plan-Apochromat objective and a sCMOS camera (Hamamatsu Flash 4.0). FISH probes were designed to target a segment of the RNA transcript encoded by the intergenic region downstream of the canonical termination sites of MRPL23 and SEL1L3. The sequences of the probes are shown in Supplementary file 1J.
Samples were barcoded and prepared for sequencing by the Centro Nacional de Análisis Genómico (CNAG, Barcelona, Spain) using Illumina protocols. PolyA+ RNA-seq libraries of ccRCC cell lines were sequenced as paired-end 75-bp sequence tags using the standard Illumina pipeline. ccRCC RNA-seq datasets (with at least 40 million mapped reads on each tumor and matched normal samples – in a total of 50 paired-samples listed in Supplementary file 1A) were obtained from TCGA. HEK293 RNA-seq data were from the Sequence Read Archive (SRX876600). RNA-seq data from SETD2 KO ccRCC cells (786-O), SETD2-depleted human MS cells and Setd2 KO mouse ES cells were obtained from the GEO (http://www.ncbi.nlm.nih.gov/geo/ GSE66879, GSE19373 and GSE54932, respectively). Data quality was assessed with the FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) quality-control tool for high throughput sequence data. Sequence tags were then mapped to the reference human (hg19) or mouse (mm9) genomes with TopHat software using default parameters (Kim et al., 2013). Reads from samples with multiple sequencing lanes were merged and only the best score alignment was accepted for each read.
Gene annotations were obtained from UCSC knownGene and refGene tables (Karolchik et al., 2014) and merged into a single transcript model per gene using BedTools (Quinlan and Hall, 2010). Our analysis was restricted to transcriptionally active genes defined as those with expression levels higher than the 25th percentile. To identify genes with transcriptional read-through, we filtered out all genes for which there was another annotated gene in either strand within a region of 5 Kb downstream of their TTS. We also filtered out genes with an overall increase in expression level relative to the control sample. Reads were counted in 100 bp windows for the 4 Kb region downstream of the TTS and normalized for the total number of mapped reads on each sample (RPKMs) (Mortazavi et al., 2008). We considered the occurrence of transcriptional read-through when more than six 100 bp windows showed increased (at least 1.5 fold-change) RPKMs relative to control. The control samples were: Caki2 for ccRCC cell lines; the matched normal tissue sample for each ccRCC patient; control 786-O ccRCC cells for SETD2 KO 786-O cells; human MS cells for SETD2-depleted human MS cells; and wt mouse ES cells for the Setd2 KO mouse. In the ccRCC cell lines dataset, all the analysis were also performed comparing both SETD2 wt (Caki1 vs Caki2), with this comparison working as a negative control. Statistical significance of the differences between proportions of genes showing read-through was assessed using the Fisher’s exact test. RNA chimeras were detected using the fusion-search option (fusion-min-dist set to 100 bp) in TopHat alignment (Kim et al., 2013) and TopHat-Fusion (Kim and Salzberg, 2011) with default parameters. For downstream analysis we only considered RNA chimeras supported by at least two reads. A set of in-house scripts were written in bash and in the R environmental language (http://www.R-project.org/) (Team RDC, 2011).
Figures were produced using BedTools (Quinlan and Hall, 2010) and default packages from the R environment. To produce heatmaps and metagene average profiles showing transcription read-through, genes were scaled to 60 equally sized bins so that all annotated TSSs and TTSs were aligned. Regions 4 Kb upstream of TSSs and 4 Kb downstream of TTSs were averaged in a 100-bp window. Individual gene profiles were produced by successions of 10-bp windows (single gene) or 100-bp windows (two genes). All read counts were normalized by genomic region length and number of mapped reads (RPKM), and RPKM values were log2 transformed when representing multiple genes. Protein levels assessed by reverse phase protein array (RPPA) were gathered from the TCGA portal. Circle plots showing RNA chimeras distribution were produced using Circos (Krzywinski et al., 2009).
The RNA-seq data for ccRCC cell lines have been deposited in Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) database under the accession number GSE64451. ccRCC RNA-seq datasets were obtained from TCGA. HEK293 RNA-seq data were from the Sequence Read Archive (SRX876600). RNA-seq data from SETD2 KO 786-O ccRCC cells, human mesenchymal stem cells and mouse embryonic stem cells were obtained from the GEO (GSE66879, GSE19373 and GSE54932, respectively).
Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36Nature Structural & Molecular Biology 18:977–983.https://doi.org/10.1038/nsmb.2123
High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinomaOncogene, 10.1038/onc.2015.221.
Circos: an information aesthetic for comparative genomicsGenome Research 19:1639–1645.https://doi.org/10.1101/gr.092759.109
Unravelling the means to an end: RNA polymerase II transcription terminationNature Reviews Molecular Cell Biology 12:283–294.https://doi.org/10.1038/nrm3098
Mapping and quantifying mammalian transcriptomes by RNA-seqNature Methods 5:621–628.https://doi.org/10.1038/nmeth.1226
R: A Language and Environment for Statistical ComputingVienna, Austria: R Foundation for Statistical Computing.
Pan-cancer patterns of somatic copy number alterationNature Genetics 45:1134–1140.https://doi.org/10.1038/ng.2760
Chi Van DangReviewing Editor; University of Pennsylvania, United States
eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see review process). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.
Thank you for submitting your work entitled "Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma" for peer review at eLife. Your submission has been favorably evaluated by Mark McCarthy (Senior editor) and three reviewers, one of whom, Chi Dang, is a member of our Board of Reviewing Editors.
The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.
The manuscript titled, "Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma" by Grosso et al., analyzes the transcription profiles from publically available database (TCGA) of RNA-seq results from 50 ccRCC primary samples to identify improper termination events that occur in these samples. The authors identified transcriptional read-through (TRT) events in the entire genome. While this effect is noticeable it is also subtle as summarized in Figure 1C. Even though the effect occurs not exclusively in those tumors where SetD2 is mutated, grouping the tumor samples according to SetD2 mutations shows that these have an overall higher prevalence of TRT, which also correlates with higher read numbers of the adjacent gene and occurrence of chimeric transcripts. The authors conclude that mutations in the SETD2 gene, which is involved in setting H3K36 methylation along transcribed sequences, are a common feature of the ccRCC and the cause of TRT.
The same group reported previously that mutations in SETD2 are linked to reduced double-strand break repair and activation of the p53 pathway. In the current manuscript, they document a significant level of TRT in RCC, in which increased BCL2 gene expression is associated with TRT into the body of the BCL2 gene. In addition, chimeric transcripts also arise from TRT, and the fusion transcript CTSC-RAB38 is found in 20% of RCC. Using SETD2 knockout cells, the authors also documented an increase in TRT as compared with wild-type cells. Further, the authors report the formation of RNA chimeras resulting from the improper splicing of the chimeric RNAs resulting from the transcriptional read-through.
Overall, this manuscript is interesting, although their main focus, as suggested in the title, of RNA chimeras has been reported previously for ccRCC in the Nature paper published a few years ago (Nature 499,43-49 (04 July 2013) doi:10.1038/nature12222). Furthermore, a recent study in neuroblastoma revealed pervasive TRT in response to osmotic shock, which was seemingly dependent on IP3R activation (Vilborg et al. Mol Cell 2015).
While the technical aspect of this study is very well-done and the findings offer a different conceptual framework for the cancer transcriptome, they are only based on correlations and it remains unclear if they contribute to malignancy and are mechanistically linked to loss of SetD2. Without further functional evidence that the absence of SETD2 directly accounts for enhanced read-through the current work remains too preliminary. This could be achieved by knockdown of SETD2 in wild-type RCC cell lines followed by TRT measurement to determine whether loss of SETD2 function would reduce TRT. Using inducible SETD2 in SETD2 mutant RCC cell lines, one could potentially perform short term TRT measurement upon induction of SETD2 expression and/or provide colony suppression assays to document the inability to reconstitute SETD2 expression in mutant cell lines.
1) The authors claim that SETD2 mutations cause the improper readout using Caki-2 cell lines as a control. The Caki-2 cell line is also a ccRCC cell line, and the other lines used in this study show lower levels of Setd2 transcription. However, the authors should show that mutations in BAP, PBRM1 or VHL do not show any transcriptional read-through before arriving at that conclusion. It would be informative if the authors compared the levels of Setd2 with a cell line like HEK293, to get an idea as to how high it is expressed in Caki-2 cells relative to a 'normal' cell line.
2) The authors do not discuss or offer any explanations as to why the RNA chimera skips the last exon of the preceding gene and the first exon of the following gene. A comment on that observation would be interesting in the Discussion.
3) The authors should discuss the following points. Further work will be necessary to document whether chimeric transcripts produce functional oncoproteins and whether TRT results in transcripts that could increase the production of downstream genes, such as BCL2. The latter could be studied in future work through ribosome profiling and footprinting. Furthermore, direct evidence that a chimeric transcript (since it is unclear if these are indeed translated) has oncogenic functions will have to be studied in the future to justify the proposed model.https://doi.org/10.7554/eLife.09214.025
While the technical aspect of this study is very well-done and the findings offer a different conceptual framework for the cancer transcriptome, they are only based on correlations and it remains unclear if they contribute to malignancy and are mechanistically linked to loss of SetD2. Without further functional evidence that the absence of SETD2 directly accounts for enhanced read-through the current work remains too preliminary. This could be achieved by knockdown of SETD2 in wild-type RCC cell lines followed by TRT measurement to determine whether loss of SETD2 function would reduce TRT.
Following the reviewers’ request, we now provide direct measurements of transcription read-through upon SETD2 depletion in wild-type (wt) ccRCC cells. These were achieved using two distinct approaches: (a) Analysis of RNA-seq data from SETD2 wt and SETD2-knockout ccRCC cells (Figure 3E,F) and (b) RT-qPCR analysis of transcription read-through in three different genes (MRPL23, SEL1L3 and FAM46A) following RNAi-mediated knockdown of SETD2 in a wt ccRCC cell line (Figure 3—figure supplement 3). These additional data further support our conclusion that SETD2 is necessary to prevent transcription read-through.
Using inducible SETD2 in SETD2 mutant RCC cell lines, one could potentially perform short term TRT measurement upon induction of SETD2 expression and/or provide colony suppression assays to document the inability to reconstitute SETD2 expression in mutant cell lines. Without these experiments, the manuscript would not be acceptable for publication.
To evaluate if wt SETD2 can rescue the transcription read-through phenotype, we performed single-molecule RNA FISH upon transient transfection of mutant ccRCC cell lines with wt SETD2. We used FISH probes designed against a segment of the RNA transcript encoded by the intergenic region downstream of the canonical termination site of two different genes (MRPL23 and SEL1L3, Figure 4). These new data show that reconstitution of SETD2 activity in mutant ccRCC cells rescues the transcription termination defects.
Minor points:1) The authors claim that SETD2 mutations cause the improper readout using Caki-2 cell lines as a control. The Caki-2 cell line is also a ccRCC cell line, and the other lines used in this study show lower levels of Setd2 transcription. However, the authors should show that mutations in BAP, PBRM1 or VHL do not show any transcriptional read-through before arriving at that conclusion. It would be informative if the authors compared the levels of Setd2 with a cell line like HEK293, to get an idea as to how high it is expressed in Caki-2 cells relative to a 'normal' cell line.
As we show in Figure 2C, ccRCC samples with mutations in BAP, PBRM1 or VHL do have transcription read-through. However, we show that mutations in SETD2 correlate significantly with higher levels of read-through. In the revised manuscript we now present new data showing that loss of SETD2 is sufficient to cause widespread transcription read-through in a wt ccRCC cell line. Moreover, we show that ectopic expression of SETD2 in a mutant ccRCC cell line rescues the termination defects. In addition, following the referees’ suggestion, we now include HEK293 cells in the comparative analysis shown in Figure 3A. These new data reveal that HEK293 and Caki-2 cells express SETD2 at similar levels.
2) The authors do not discuss or offer any explanations as to why the RNA chimera skips the last exon of the preceding gene and the first exon of the following gene. A comment on that observation would be interesting in the Discussion.
We show in Figure 7B that the splicing pattern of the chimeras join the second-last exon of the upstream gene with the second exon of the downstream gene. We suggest that this pattern is in agreement with the exon definition model according to which the absence of transcription termination evicts the last 3’ss of the upstream gene favouring the use of the first 3’ss that emerges from the downstream gene. This model explains why the RNA chimeras skip the last exon of the upstream gene and the first exon of the downstream gene. We now comment this model in the Discussion.
3) The authors should discuss the following points. Further work will be necessary to document whether chimeric transcripts produce functional oncoproteins and whether TRT results in transcripts that could increase the production of downstream genes, such as BCL2. The latter could be studied in future work through ribosome profiling and footprinting. Furthermore, direct evidence that a chimeric transcript (since it is unclear if these are indeed translated) has oncogenic functions will have to be studied in the future to justify the proposed model.
These points are now discussed in the revised manuscript.https://doi.org/10.7554/eLife.09214.026
- Sérgio F de Almeida
- Mafalda R Matos
- Alexandra C Vítor
- Ana R Grosso
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
We thank our colleagues Nuno Barbosa-Morais, Sérgio Dias and Edgar Gomes for critical comments and suggestions. We also thank Ioana Posa, Mafalda Pimentel, Célia Carvalho and the Bioimaging Unit of the IMM for technical assistance. This work was supported by Fundação para a Ciência e Tecnologia (FCT), Portugal (PTDC/BIM-ONC/0384-2012 to SFdA). MRM is a FCT PhD fellow (SFRH/BD/92208/2013). ACV is a Lisbon BioMed PhD fellow funded by FCT (SFRH/BD/52232/2013). ARG is the recipient of a FCT Investigator award (IF/00510/2014).
- Chi Van Dang, University of Pennsylvania, United States
© 2015, Grosso et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.